I agree that a partnership would be a likely outcome in a case where Race had more confidence in the future potential and value of Bisantrene (i.e. application to a broader range of cancers and potential new indications), and were prepared to take more risk and be patient. I'm not yet convinced that will be the case though.
At the time of a transaction, Race will surely share all of their information and data - the BP scientists and doctors should be able to come to similar conclusions as to the potential and risks as our expert team in Race. A cash buyout offer, suitably discounted for the ongoing execution risks, could still be reached (gotta leave some value on the table to reach a deal). I recall on a much early thread that a partnership deal was not the board/management's preferred option.
Either way, will factor the prospect of a partnership deal into retirement planning (although much prefer a clean cash deal).
- Forums
- ASX - By Stock
- RAC
- What's going on with Race Oncology at the moment ?
What's going on with Race Oncology at the moment ?, page-45
-
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M |
Open | High | Low | Value | Volume |
$1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | $1.94 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.95 | 7574 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3105 | 1.940 |
2 | 30000 | 1.900 |
1 | 4861 | 1.880 |
1 | 3000 | 1.850 |
1 | 30000 | 1.840 |
Price($) | Vol. | No. |
---|---|---|
1.950 | 7574 | 1 |
1.995 | 10037 | 1 |
2.000 | 8000 | 3 |
2.020 | 4000 | 1 |
2.040 | 2000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |